Seaport Therapeutics doses first patient in Phase 2a GAAD trial
Seaport Therapeutics, a PureTech-founded entity, said the first patient was dosed in a Phase 2a trial of GlyphAgo™ for generalized anxiety disorder and sleep disturbance.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.